288 related articles for article (PubMed ID: 29144113)
1. [Can we transfer the mechanisms of the generics market to biosimilars?].
Jacke CO; Wild F
Versicherungsmedizin; 2016 Dec; 68(4):168-72. PubMed ID: 29144113
[TBL] [Abstract][Full Text] [Related]
2. [The importance of biosimilars medicines for private and statutory health insurance].
Bretthauer B
Versicherungsmedizin; 2016 Dec; 68(4):173-5. PubMed ID: 29144116
[TBL] [Abstract][Full Text] [Related]
3. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.
Lee HJ; Han E; Kim H
Appl Health Econ Health Policy; 2020 Aug; 18(4):557-566. PubMed ID: 31930450
[TBL] [Abstract][Full Text] [Related]
5. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Dutta B; Huys I; Vulto AG; Simoens S
BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
[TBL] [Abstract][Full Text] [Related]
6. Business of biosimilars - 14th annual conference (October 15-17, 2013 - Boston, Massachusetts, USA).
Bourgoin A
Drugs Today (Barc); 2013 Dec; 49(12):799-801. PubMed ID: 24524098
[TBL] [Abstract][Full Text] [Related]
7. Joint 24th Medicines for Europe and 21st International Generic and Biosimilars Association (IGBA) Annual Conference (June 13-15, 2018 - Budapest, Hungary).
Cross G
Drugs Today (Barc); 2018 Aug; 54(8):499-505. PubMed ID: 30209444
[TBL] [Abstract][Full Text] [Related]
8. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
Grabowski HG; Guha R; Salgado M
Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
[TBL] [Abstract][Full Text] [Related]
9. [Biosimilars and the efficiency principle].
Münnch T
Laryngorhinootologie; 2017 Dec; 96(12):828-830. PubMed ID: 29195262
[TBL] [Abstract][Full Text] [Related]
10. [Experiences with price competition of biosimilar drugs in Hungary].
Hornyák L; Nagy Z; Tálos Z; Endrei D; Ágoston I; Csákvári T; Boncz I
Acta Pharm Hung; 2014; 84(2):83-7. PubMed ID: 25167704
[TBL] [Abstract][Full Text] [Related]
11. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
12. Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices.
Curto S; Ghislandi S; van de Vooren K; Duranti S; Garattini L
Health Policy; 2014 Jun; 116(2-3):182-7. PubMed ID: 24602376
[TBL] [Abstract][Full Text] [Related]
13. Some drugs more equal than others: pseudo-generics and commercial practice.
Probyn AJ
Aust Health Rev; 2004 Nov; 28(2):207-17. PubMed ID: 15527401
[TBL] [Abstract][Full Text] [Related]
14. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
15. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
Kong Y
Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
Falit BP; Singh SC; Brennan TA
Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
[TBL] [Abstract][Full Text] [Related]
17. Sustaining competition for biosimilars on the pharmacy benefit: Use it or lose it.
Mehr SR
J Manag Care Spec Pharm; 2024 Jun; 30(6):600-603. PubMed ID: 38824633
[TBL] [Abstract][Full Text] [Related]
18. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars in Dermatology: Current Situation (Part I).
Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
Actas Dermosifiliogr; 2015 Sep; 106(7):545-9. PubMed ID: 25987472
[TBL] [Abstract][Full Text] [Related]
20. [Prescription of generic drugs to privately insured persons].
Wild F
Versicherungsmedizin; 2012 Dec; 64(4):190-2. PubMed ID: 23236709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
